Bluefish Pharmaceuticals convertible debt issue provides SEK 35 million


Bluefish Pharmaceuticals has completed the issue of convertibles which will provide the company with gross proceeds of 35 SEK million. The convertibles will be delivered once the transaction has been registered by the Swedish Companies Registration office. Assuming full conversion of the convertible debt into common stock, the number of new B shares in Bluefish could increase by 4 200 980 and the share capital could increase by SEK 840 196. The intention of the convertible debt issue has been to secure the company's increased need for working capital as the company is launching its product portfolio in additional EU markets.

About Us

Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of 80 products and is growing. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.